Rheumatoid arthritis market set for only modest growth by 2020

9 June 2015

The rheumatoid arthritis market is set to grow modestly in value between 2013 and 2020, at a compound annual growth rate (CAGR) of 4.1%.

GBI Research says that the increase, from $14.3 billion in 2013 to just over $19 billion in 2020, will be driven by the approval of new biologics, including Enbrel (etanercept) from Amgen (Nasdaq: AMGN), Remicade (infliximab) from Janssen (NYSE: JNJ) and Humira (adalimumab) from AbbVie (NYSE: ABBV).

Yasser Mushtaq, a senior analyst at GBI, said: "Prior to 1998, treatment options were limited to small-molecule disease-modifying therapies, such as methotrexate, sulfasalazine and antimalarials. However, approximately 33% of all patients are unresponsive to these first-line drugs. Second-line Tumor Necrosis Factor Alpha (TNF-α)-targeting biologics, Humira, Remicade and Enbrel, were ranked among the top 10 best-selling drugs in the world in 2013, with respective global revenues of $11.1 billion, $9.9 billion and $8.9 billion."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >